| Literature DB >> 21510829 |
Jessica Lee Yarber1, Mark Agulnik.
Abstract
INTRODUCTION: Bone sarcomas are rare malignancies and once advanced, there is limited response to current chemotherapeutic regimens. Targeted therapies could have substantial impact on these diseases. AREAS COVERED: Specific molecular targets of bone sarcomas are reviewed along with the various targeted therapies that have potential to change the outcome of these chemotherapy resistant diseases. EXPERT OPINION: There are promising pathways identified that targeted inhibitors could provide better treatment options for metastatic bone sarcomas. There is a strong need for continued Phase II and III clinical trials investigating these molecularly targeted therapies.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21510829 DOI: 10.1517/13543784.2011.577064
Source DB: PubMed Journal: Expert Opin Investig Drugs ISSN: 1354-3784 Impact factor: 6.206